Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 191,806,368
  • Shares Outstanding, K 5,967,840
  • Annual Sales, $ 52,824 M
  • Annual Income, $ 7,215 M
  • 36-Month Beta 0.98
  • Price/Sales 3.63
  • Price/Cash Flow 9.51
  • Price/Book 3.26

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.97 +0.53%
on 05/25/17
34.02 -5.53%
on 04/27/17
-1.71 (-5.05%)
since 04/26/17
3-Month
31.97 +0.53%
on 05/25/17
34.75 -7.51%
on 03/02/17
-2.12 (-6.19%)
since 02/24/17
52-Week
29.83 +7.74%
on 11/03/16
37.39 -14.04%
on 08/01/16
-2.29 (-6.65%)
since 05/26/16

Most Recent Stories

More News
September 2018 Options Now Available For Pfizer (PFE)

Investors in Pfizer Inc saw new options become available today, for the September 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value,...

PFE : 32.14 (-0.06%)
Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote

Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.

JNJ : 126.92 (-0.48%)
MRK : 64.92 (-0.18%)
AMGN : 155.01 (-0.27%)
PFE : 32.14 (-0.06%)
Celldex's Immuno-Oncology Pipeline Continues to Impress

On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).

CLDX : 3.06 (-1.29%)
MRK : 64.92 (-0.18%)
PFE : 32.14 (-0.06%)
BMY : 53.97 (-0.77%)
Blog Coverage: Pfizer Cautions Shareholders Against Accepting TRC Capital Corporation's Mini-Tender Offer

Upcoming AWS Coverage on AbbVie Post-Earnings Results

TU : 34.14 (+0.06%)
BCE : 45.16 (unch)
KR : 29.45 (+0.72%)
XOM : 81.55 (-0.24%)
ENB : 38.96 (-0.87%)
ABBV : 66.06 (-0.39%)
PFE : 32.14 (-0.06%)
Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data

Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.

AERI : 55.90 (+3.04%)
MRK : 64.92 (-0.18%)
LLY : 78.05 (-0.37%)
GWPH : 106.13 (-1.75%)
PFE : 32.14 (-0.06%)
SNY : 49.00 (-0.06%)
BMY : 53.97 (-0.77%)
Aerie's Ophthalmic Candidate Positive in Registration Trial

Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan.

AERI : 55.90 (+3.04%)
VVUS : 1.13 (+0.89%)
AGN : 223.12 (-0.55%)
PFE : 32.14 (-0.06%)
How These Healthcare Stocks are Faring? -- Pfizer, Zoetis, Mallinckrodt, and Patheon

Stock-Callers.com revisits the Healthcare sector, which is an aggregation and integration of sectors within the economic system that provides goods and services to treat patients with curative, preventive,...

ZTS : 62.61 (+0.05%)
MNK : 43.28 (+5.56%)
PFE : 32.14 (-0.06%)
PTHN : 34.55 (-0.17%)
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Corporation

Pfizer Inc. (NYSE:PFE) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Corporation of Ontario, Canada to purchase up to 4 million shares of...

PFE : 32.14 (-0.06%)
Investors: Option reports for Citigroup, The Gap, Nike, NVIDIA and Pfizer Inc. include trade ideas that offer returns of 18% or more!

InvestorsObserver issues critical PriceWatch Alerts for C, GPS, NKE, NVDA, and PFE.

NVDA : 141.84 (+2.59%)
C : 62.07 (+0.19%)
NKE : 52.59 (+0.46%)
GPS : 22.42 (+1.82%)
PFE : 32.14 (-0.06%)
Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug

Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.

AGLE : 4.50 (+1.58%)
VVUS : 1.13 (+0.89%)
SHPG : 177.18 (-4.13%)
PFE : 32.14 (-0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Support & Resistance

2nd Resistance Point 32.37
1st Resistance Point 32.25
Last Price 32.14
1st Support Level 32.06
2nd Support Level 31.99

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.